The Week In... Pharma (30/09-04/10)
  • Posted on: 04/10/2019
  • Category: Industry

The Week In... Pharma (30/09-04/10)

The value of pharma ‘ecosystems’ is discussed, the Pf Power List 2019 is revealed, the NAO says there will be delays in medicine supplies in a no-deal Brexit, and how can China’s pharma market offer opportunities for UK drug manufacturers? 

Interested in Star’s innovative outsourcing and resourcing solutions? 

Contact Operations Director, Mark Ward, on 07872 105 540 or email mark.ward@starmedical.co.uk. 

On the hunt for a new role, or just curious? 

Visit our candidate page, submit your CV to candidates@starmedical.co.uk, or give our offices a ring! 

Pf Power List 2019: Who is shaping the pharma & healthcare sector?

The Pf Power List has looked at who is making a difference in pharma and healthcare in 2019.

UK audit body finds no-deal Brexit drug supply preparation lacking

The UK National Audit Office has released a report which has found that medicine supply to the UK will be delayed in the event of a no-deal Brexit.

Opening doors

China’s pharmaceutical market increasingly offers opportunities for UK drug-makers.

Academia: An important player in the drug discovery ecosystem

Dr Richard Angell and Dr Jane Kinghorn from the Drug Discovery Group (Translational Research Office), at University College London (UCL), explain the value of drug discovery in academia in bridging the “Valley of Death”.

Ecosystems – the new networks of global innovation

Great science is increasingly the product of a web of interdependent enterprises and relationships functioning together to create value.

While you’re here…

…and are interested in our content, why not sign up to our newsletter?

It’s just below here.